1. Home
  2. DSP vs MXCT Comparison

DSP vs MXCT Comparison

Compare DSP & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$11.77

Market Cap

184.3M

Sector

Technology

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.50

Market Cap

186.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
MXCT
Founded
1999
1999
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.3M
186.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DSP
MXCT
Price
$11.77
$1.50
Analyst Decision
Strong Buy
Buy
Analyst Count
8
4
Target Price
$18.50
$7.50
AVG Volume (30 Days)
261.6K
1.3M
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
29.49
N/A
EPS
0.10
N/A
Revenue
$324,131,000.00
$34,419,000.00
Revenue This Year
$17.79
N/A
Revenue Next Year
$17.72
$10.69
P/E Ratio
$120.95
N/A
Revenue Growth
22.97
N/A
52 Week Low
$8.11
$1.26
52 Week High
$26.33
$5.20

Technical Indicators

Market Signals
Indicator
DSP
MXCT
Relative Strength Index (RSI) 60.87 44.92
Support Level $11.10 $1.47
Resistance Level $12.26 $1.54
Average True Range (ATR) 0.50 0.10
MACD -0.03 -0.01
Stochastic Oscillator 56.45 30.77

Price Performance

Historical Comparison
DSP
MXCT

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Share on Social Networks: